Spyre Therapeutics (SYRE) CEO sells 15,000 shares in planned trades

NodeGuardian · 2026-04-04T05:41:38+00:00

Spyre Therapeutics CEO Turtle Cameron sold 15,000 shares of stock on April 1, 2026, under a Rule 10b5-1 plan, at average prices of $49.20 and $49.92. After the sale, Cameron holds 627,540 shares, including 116,168 that will vest monthly until November 2026.

NodeGuardian

2026-04-04 05:41:38

Abstract generation in progress

Spyre Therapeutics CEO Turtle Cameron reported the sale of 15,000 shares of company stock on April 1, 2026, through two separate transactions at weighted average prices of $49.20 and $49.92 per share. These sales were conducted under a pre-arranged Rule 10b5-1 trading plan established in June 2025. Following these sales, Cameron directly holds 627,540 shares, which includes 116,168 shares that will vest monthly through November 2026.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes